These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

921 related articles for article (PubMed ID: 16244542)

  • 1. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification.
    Schneider PM; Baldus SE; Metzger R; Kocher M; Bongartz R; Bollschweiler E; Schaefer H; Thiele J; Dienes HP; Mueller RP; Hoelscher AH
    Ann Surg; 2005 Nov; 242(5):684-92. PubMed ID: 16244542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Relevance of Lymph Node Regression After Neoadjuvant Chemoradiation for Esophageal Cancer.
    Philippron A; Bollschweiler E; Kunikata A; Plum P; Schmidt C; Favi F; Drebber U; Hölscher AH
    Semin Thorac Cardiovasc Surg; 2016 Summer; 28(2):549-558. PubMed ID: 28043475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer.
    Xi H; Baldus SE; Warnecke-Eberz U; Brabender J; Neiss S; Metzger R; Ling FC; Dienes HP; Bollschweiler E; Moenig S; Mueller RP; Hoelscher AH; Schneider PM
    Clin Cancer Res; 2005 Dec; 11(23):8341-7. PubMed ID: 16322294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced incidence of nodal micrometastasis after major response to neoadjuvant chemoradiation in locally advanced esophageal cancer.
    Prenzel KL; König A; Schneider PM; Schnickmann C; Baldus SE; Schröder W; Bollschweiler E; Dienes HP; Mueller RP; Izbicki JR; Hölscher AH
    Ann Surg Oncol; 2007 Feb; 14(2):954-9. PubMed ID: 17103071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic classification of histopathologic response to neoadjuvant therapy in esophageal adenocarcinoma.
    Hölscher AH; Drebber U; Schmidt H; Bollschweiler E
    Ann Surg; 2014 Nov; 260(5):779-84; discussion 784-5. PubMed ID: 25379849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas.
    Brücher BL; Becker K; Lordick F; Fink U; Sarbia M; Stein H; Busch R; Zimmermann F; Molls M; Höfler H; Siewert JR
    Cancer; 2006 May; 106(10):2119-27. PubMed ID: 16607651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer.
    Schneider PM; Metzger R; Schaefer H; Baumgarten F; Vallbohmer D; Brabender J; Wolfgarten E; Bollschweiler E; Baldus SE; Dienes HP; Hoelscher AH
    Ann Surg; 2008 Dec; 248(6):902-8. PubMed ID: 19092334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Extent of Lymphadenectomy on Survival, Post Neoadjuvant Chemotherapy and Transthoracic Esophagectomy.
    Phillips AW; Lagarde SM; Navidi M; Disep B; Griffin SM
    Ann Surg; 2017 Apr; 265(4):750-756. PubMed ID: 27467444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histological regression of squamous esophageal carcinoma assessed by percentage of residual viable cells after neoadjuvant chemoradiation is an important prognostic factor.
    Tong DK; Law S; Kwong DL; Chan KW; Lam AK; Wong KH
    Ann Surg Oncol; 2010 Aug; 17(8):2184-92. PubMed ID: 20217248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of ABCB1 C3435T polymorphism on lymph node regression in multimodality treatment of locally advanced esophageal cancer.
    Narumiya K; Metzger R; Bollschweiler E; Alakus H; Brabender J; Drebber U; Hölscher AH; Warnecke-Eberz U
    Pharmacogenomics; 2011 Feb; 12(2):205-14. PubMed ID: 21332314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response.
    Barbour AP; Jones M; Gonen M; Gotley DC; Thomas J; Thomson DB; Burmeister B; Smithers BM
    Ann Surg Oncol; 2008 Oct; 15(10):2894-902. PubMed ID: 18663531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Failure in downregulation of intratumoral survivin expression following neoadjuvant chemoradiation in esophageal cancer.
    Vallböhmer D; Kuhn E; Warnecke-Eberz U; Brabender J; Hoffmann AC; Metzger R; Baldus SE; Drebber U; Hoelscher AH; Schneider PM
    Pharmacogenomics; 2008 Jun; 9(6):681-90. PubMed ID: 18518847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.
    Castoro C; Scarpa M; Cagol M; Ruol A; Cavallin F; Alfieri R; Zanchettin G; Rugge M; Ancona E
    Ann Surg Oncol; 2011 Dec; 18(13):3743-54. PubMed ID: 21556952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Who profits from neoadjuvant radiochemotherapy for locally advanced esophageal carcinoma?
    Kersting S; Konopke R; Dittert D; Distler M; Rückert F; Gastmeier J; Baretton GB; Saeger HD
    J Gastroenterol Hepatol; 2009 May; 24(5):886-95. PubMed ID: 19655439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer.
    Watanabe M; Baba Y; Yoshida N; Ishimoto T; Nagai Y; Iwatsuki M; Iwagami S; Baba H
    Ann Surg Oncol; 2014 Sep; 21(9):2838-44. PubMed ID: 24715216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. External Validation of Pretreatment Pathological Tumor Extent in Patients with Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer.
    Brinkmann S; Noordman BJ; Hölscher AH; Biermann K; van Klaveren D; Bollschweiler E; Pütz K; van Lanschot JJB; Drebber U
    Ann Surg Oncol; 2020 Apr; 27(4):1250-1258. PubMed ID: 31691114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response.
    Blackham AU; Yue B; Almhanna K; Saeed N; Fontaine JP; Hoffe S; Shridhar R; Frakes J; Coppola D; Pimiento JM
    J Surg Oncol; 2015 Nov; 112(6):597-602. PubMed ID: 26394724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncologic Outcomes According to Remnant Lymph Node Metastases in Pathologic T0 (ypT0) Esophageal Squamous Cell Carcinoma Following Prospective Neoadjuvant Therapy and Surgery.
    Cho HJ; Kim YH; Kim HR; Kim DK; Park SI; Kim JH; Kim SB
    Ann Surg Oncol; 2015; 22(6):1851-7. PubMed ID: 25344308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.
    Shridhar R; Hoffe SE; Almhanna K; Weber JM; Chuong MD; Karl RC; Meredith K
    Ann Surg Oncol; 2013 Sep; 20(9):3038-43. PubMed ID: 23625142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of clinical T2N0M0 esophageal cancer.
    Hardacker TJ; Ceppa D; Okereke I; Rieger KM; Jalal SI; LeBlanc JK; DeWitt JM; Kesler KA; Birdas TJ
    Ann Surg Oncol; 2014 Nov; 21(12):3739-43. PubMed ID: 25047477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.